share_log

Benchmark Maintains Speculative Buy on ImmunoPrecise Antibodies, Lowers Price Target to $7

Benzinga ·  Mar 21, 2023 12:32

Benchmark analyst Robert Wasserman maintains ImmunoPrecise Antibodies (NASDAQ:IPA) with a Speculative Buy and lowers the price target from $12 to $7.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment